Namwiwat Medical PCLBKK:NAM -1.73%40 PB Ratio is 1.19 as of Jul. 07, 2026, which is 21% below its 10-year median of 1.50. GuruFocus rates BKK:NAM with a GF Score™ of 40/100 and a GF Value™ of ฿6.04 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks better than 73.35% on this metric.
Namwiwat Medical Corp PCL stock PB Ratio (=1.2) is close to 3-year low of 1.2.
The historical rank and industry rank for Namwiwat Medical PCL's PB Ratio or its related term are showing as below:
BKK:NAM'
s PB Ratio Range Over the Past 10 Years
Min: 1.19 Med: 1.5 Max: 4.26
Current: 1.19
During the past 6 years, Namwiwat Medical PCL's highest PB Ratio was 4.26. The lowest was 1.19. And the median was 1.50.
BKK:NAM's PB Ratio is ranked better than 73.35% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs BKK:NAM: 1.19
During the past 12 months, Namwiwat Medical PCL's average Book Value Per Share Growth Rate was -5.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 18.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 55.20% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Namwiwat Medical PCL was 96.20% per year. The lowest was 18.20% per year. And the median was 68.40% per year.
Back to Basics: PB Ratio
Namwiwat Medical PCL (BKK:NAM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Namwiwat Medical PCL PB Ratio Related Terms
Namwiwat Medical PCL PB Ratio Historical Data
* Premium members only.
The historical data trend for Namwiwat Medical PCL's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Namwiwat Medical PCL's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's PB Ratio distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Namwiwat Medical PCL (BKK:NAM) has a PB Ratio of 1.19 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Namwiwat Medical PCL and its competitors. This is 21% below median its historical median of 1.50. Over the past decade, Namwiwat Medical PCL's PB Ratio has ranged from 1.19 to 4.26. According to the industry distribution chart, Namwiwat Medical PCL ranks #210 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 26.6%.
Is Namwiwat Medical PCL's PB Ratio too high?
Namwiwat Medical PCL's current PB Ratio of 1.19 is 21% below median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 4.26. The Medical Devices & Instruments industry median PB Ratio is 2.05. Namwiwat Medical PCL's value of 1.19 is 42% below this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #210 out of 788 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 40/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #210 out of 788 companies for PB Ratio. This puts Namwiwat Medical PCL in the upper half of its industry. The industry median PB Ratio is 2.05. Namwiwat Medical PCL's value of 1.19 is 42% below this benchmark. Historically, Namwiwat Medical PCL's own PB Ratio has ranged from 1.19 to 4.26 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 2.05, Namwiwat Medical PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current PB Ratio of 1.19 is 42% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current PB Ratio is 1.19, which is 21% below median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.04, compared to a current price of ฿3.40 — trading 43.7% below its estimated fair value. The current PB Ratio is 1.19, which is 21% below median its 10-year median of 1.50 and 42% below the Medical Devices & Instruments industry median of 2.05. Namwiwat Medical PCL's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current PB Ratio is 1.19 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.40 is trading 43.7% below its estimated GF Value™ of ฿6.04.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
PB Ratio: 1.19 (21% below median its 10-year median of 1.50)
GF Value™: ฿6.04 vs. price of ฿3.40 (43.7% below fair value)
Industry Position: 42% below the Medical Devices & Instruments median (#210 of 788)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
40GF Score
Get the complete analysis for BKK:NAM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
